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The tumor microenvironment (TME) plays an essential role in thedevelopment, growth, and survival of the malignant B-cell clone inchronic lymphocytic leukemia (CLL). Within the proliferation nich-
es of lymph nodes, bone marrow, and secondary lymphoid organs, a vari-
ety of phenotypically and functionally altered cell types, including T cells,
natural killer cells, monocytes/macrophages, endothelial and mesenchy-
mal stroma cells, provide crucial survival signals, along with CLL-cell-
induced suppression of antitumor immune responses. The B-cell receptor
pathway plays a pivotal role in mediating the interaction between CLL
cells and the TME. However, an increasing number of additional compo-
nents of the multifactorial TME are being discovered. Although the major-
ity of therapeutic strategies employed in CLL hitherto have focused on tar-
geting the leukemic cells, emerging evidence implies that modulation of
microenvironmental cells and CLL-TME interactions by novel therapeutic
agents significantly affect their clinical efficacy. Thus, improving our
understanding of CLL-TME interactions and how they are affected by cur-
rent therapeutic agents may improve and guide treatment strategies.
Identification of novel TME interactions may also pave the road for the
development of novel therapeutic strategies targeting the TME. In this
review, we summarize current evidence on the effects of therapeutic
agents on cells and interactions within the TME. With a growing demand
for improved and personalized treatment options in CLL, this review aims
at inspiring future exploration of smart drug combination strategies, trans-
lational studies, and novel therapeutic targets in clinical trials.
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Chronic lymphocytic leukemia (CLL) is a B-cell malignancy characterized by the
clonal expansion of CD5+/CD19+ malignant B cells, and displays a heterogeneous
pathology with chromosomal aberrations, recurrent mutations, and microenviron-
mental involvement.1 Although characterized by an accumulation of malignant
cells in peripheral blood, CLL develops in protective niches and proliferation cen-
ters within the bone marrow, lymph nodes, the spleen and, more rarely, the liver.2
These tissues allow close interactions between malignant cells and various host
cells constituting the tumor microenvironment (TME). The survival and growth of
CLL cells is highly dependent on support from these surrounding microenviron-
mental cells that include T cells, monocytes/macrophages, endothelial and mes-
enchymal stroma cells, and natural killer (NK) cells.2-5 The complex crosstalk
between CLL cells and these essential microenvironmental components is still
poorly defined but studies have revealed how these interactions support disease
progression and drug resistance.6-9 For an extensive and detailed overview of the
CLL-TME constituents and interactions, we refer the reader to previously pub-
lished reviews,3-5 as a complete review of the CLL TME is beyond the scope of this
review. However, key components and interactions relevant for the contents of this
review are briefly highlighted here.
REVIEW ARTICLE
The T-cell compartment in CLL has a complex dual role
since it can exert both pro-tumor as well as anti-CLL cyto-
toxic activity.10 Recruited CD4+ T helper cells (Th cells)
within proliferation centers provide tumor support
through CD40/CD40 ligand (CD40L) co-stimulation and
cytokine signaling.11,12 In the peripheral blood of patients,
T-cell numbers are increased with skewing towards cyto-
toxic CD8+ T cells and enriched effector cell subpopula-
tions.13 Both CD4+ and CD8+ T-cell subpopulations exhibit
functional defects including impaired immune synapse
formation with antigen-presenting cells, impaired
cytokine production, degranulation, and antitumor cyto-
toxicity.14-16 Furthermore, T cells in CLL show increased
expression of markers of chronic activation and exhaus-
tion, such as programmed cell death protein 1 (PD-1),13,16
contributing to inhibited effector function and impaired
immunological synapse formation.15,16 Patients with CLL
also have elevated numbers of regulatory T cells (Treg), a
subset of immunosuppressive T cells that constitute sig-
nificant suppressors of antitumor T-cell responses.17 Thus,
Th cells play an important supportive role in CLL, whereas
the accumulation of Treg and exhausted cytolytic T cells
prevent effective anti-CLL effector functions.
Similarly, myeloid cells in CLL play both tumor-support-
ive and immunosuppressive roles. These cells include
nurse-like cells (NLC), which constitute an essential
tumor-supporting component of the TME. NLC, generat-
ed in vitro, protect CLL cells from spontaneous and drug-
induced apoptosis, promote migration, and aid recruit-
ment of tumor-supportive T cells.18-20 Importantly, NLC
reveal a strong resemblance to tumor-associated
macrophages infiltrating lymph node tissue in CLL.21 In
contrast, myeloid cells with immunosuppressive proper-
ties, termed myeloid-derived suppressor cells (MDSC),
accumulate in the peripheral blood of CLL patients.22 In
vitro, CLL-induced MDSC suppress T-cell effector function
and promote Treg differentiation.23 Thus, MDSC represent
a significant immunosuppressive component within the
CLL-TME.
Co-culturing CLL cells with bone marrow-derived stro-
mal cells or endothelial cells abrogates the spontaneous
apoptosis of CLL cells in vitro, highlighting the supportive
role of stromal cells in the CLL-TME.24 Stromal cells medi-
ate lymphocyte trafficking and homing, and promote CLL
survival and proliferation by inducing expression of pro-
angiogenetic and anti-apoptotic proteins.19,24 Thus, the
CLL-TME constitutes a complex cellular and molecular
network that contributes to tumor survival and immune
suppression.
The B-cell receptor pathway is a central mechanism by
which CLL cells maintain their crucial interaction with the
TME. It consists of an antigen-binding transmembrane
immunoglobulin connected to downstream regulators
including spleen tyrosine kinase (SYK), Bruton tyrosine
kinase (BTK), and phosphoinositide-3-kinase δ (PI3Kδ)
(Figure 1A). B-cell receptor signaling, recently reviewed
elsewhere,25 promotes proliferation, survival, and migra-
tion of the malignant clone. Stimulation of B-cell activat-
ing factor receptor (BAFF-R) by its ligand B-cell activating
factor (BAFF) provided by, for example, NLC in the TME,
also promotes important pro-survival and growth sig-
nals.26 Furthermore, through direct cell-cell contact by co-
expressed adhesion molecules such as lymphocyte func-
tion-associated antigen-1 (LFA-1) and intercellular adhe-
sion molecule-1, and chemokine signaling via the CXC
motif chemokine receptor (CXCR)4/CXC ligand
(CXCL)12 axis, TME constituents, such as NLC and stro-
mal cells, aid migration and homing of CLL cells into pro-
tective niches.4,18,19,24 
Reciprocally, CLL cells release cytokines including inter-
leukin (IL)-6 and IL-10,27,28 chemokines such as CCL2,12 and
extracellular vesicles,4,29 through which they recruit and
alter microenvironmental cells, thus inducing a tumor-sup-
portive niche. The above highlighted CLL-TME con-
stituents and interactions are summarized in Online
Supplementary Figure S1.
The immune-subversive milieu preventing the host
immune system from eliminating CLL cells also entails a
state of clinical immune dysfunction, manifested as an
increased risk of infections and autoimmune conditions in
patients with CLL.30 Thus, the CLL-TME is not merely a
“silent” support system for malignant cells, but contributes
significantly to clinical presentation and disease aggres-
siveness.
The majority of therapeutic strategies employed hither-
to have been designed to target the survival axes of CLL
cells, as exemplified by the development of inhibitor drugs
targeting the B-cell receptor pathway. However, as our
knowledge on the mechanisms of action is expanding,
there is emerging evidence that targeted agents modulate
immune TME cells and interactions, which likely pro-
foundly influences clinical responses. These effects occur
both indirectly, through elimination of CLL cells and/or
disruption of critical CLL-TME interaction pathways, and
directly, through inhibition of targets within the specific
TME cells (Figure 1B). Furthermore, some novel treatment
modalities rely directly on the engagement and activation
of microenvironmental cells for their anti-CLL activity
(Figure 1B).
In order to improve tailored treatment options for
patients with CLL, and ultimately improve the clinical
course of the disease, a better understanding of how cur-
rent novel therapies affect the CLL-TME is warranted.
Here we review the current knowledge on how novel tar-
geted therapies modulate CLL-TME cells and their interac-
tions. We discuss implications for future treatment strate-
gies and the development of combination therapy, and
highlight potential novel therapeutic targets that warrant
future exploration. 
BTK inhibitors
The introduction of small molecule inhibitors of BTK, a
TEC family kinase that plays a crucial role downstream of
B-cell receptor signaling, has shifted the paradigm for CLL
treatment during the past decade. Ibrutinib (PCI-32765)
was the first oral covalent BTK inhibitor to be approved
for CLL by the Food and Drug Administration. Second-
generation BTK inhibitors, acalabrutinib and zanubruti-
nib, are currently being introduced into clinical use.31,32
BTK inhibition by ibrutinib inhibits activation-induced
proliferation and induces apoptosis of CLL cells.33
However, a growing number of studies describe effects of
ibrutinib on several components of the TME. 
Changes in total T-cell numbers induced by ibrutinib are
controversial, as studies have documented both increased
and decreased total T-cell numbers in patients treated with
ibrutinib.34-36 This discrepancy may be due to differences in
treatment duration and disease status at the time of fol-
R. Svanberg et al.
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low-up, as well as differences between cohorts of patients.
Increased T-cell numbers were observed during the first 6
months of treatment in one study,35 while a decrease and
normalization of T-cell numbers were found in studies
with longer follow-up.33,34,36 This may suggest a correlation
between T-cell dynamics and CLL tumor burden during
ibrutinib treatment. It was previously demonstrated that
T-cell receptor repertoire diversity increased in patients
upon ibrutinib treatment, which correlated with disease
response and lower infection rates.34 Interestingly, an
increase in clonal T cells during ibrutinib treatment, which
could be linked to residual CLL disease persistence and the
co-occurrence of anti-CLL T-cell clones, was reported
recently,37 suggesting that residual disease may maintain
certain, specific anti-CLL T-cell clones. Thus, reduced
tumor burden as an indirect effect of ibrutinib likely con-
tributes significantly to normalization of the majority of
the T-cell repertoire along with T-cell numbers. Ibrutinib
exhibits off-target activity against IL-2-inducible T-cell
kinase (ITK), a TEC kinase signaling downstream of the T-
cell receptor, which plays a role in T-cell activation,
cytokine release, and proliferation.38 The second-genera-
tion BTK inhibitors, acalabrutinib and zanubrutinib, have
increased BTK selectivity but an insignificant inhibitory
effect on ITK.39,40 In contrast to ibrutinib, treatment with
acalabrutinib and zanubrutinib did not alter patients’ T-
cell numbers; however, the follow-up time in these studies
was limited to 6-7 months, when residual disease may still
be present.35,40 Thus, further studies are warranted to clari-
fy the potential contribution of direct ITK inhibition to the
changes in T-cell numbers seen with ibrutinib. 
It was also demonstrated that ibrutinib restored T-cell
proliferation and degranulation,36 enhanced T-cell lytic
immune synapse function,41 and reversed the
Figure 1. Overview of targets within the chronic lymphocytic leukemia cell, and
mechanisms of tumor microenvironment modulation by targeted agents. (A)
The chronic lymphocytic leukemia (CLL) cell including targets within the B-cell
receptor pathway and anti-apoptotic pathway. Downstream of the B-cell receptor,
BTK is inhibited by ibrutinib, acalabrutinib, and zanubrutinib, and PI3Kδ is inhib-
ited by idelalisib, duvelisib, and umbralisib. The anti-apoptotic protein BCL-2 is
inhibited by venetoclax. (B) Direct versus indirect effects of targeted agents, and
activation of tumor microenvironment (TME) anti-CLL activity by novel treatment
modalities. Inhibition (both on- and off-target) of targets within the specific TME
cells are here referred to as direct effects, exemplified by off-target inhibition of
ITK in T cells by ibrutinib, and (on-target) inhibition of PI3Kδ in T cells by idelalis-
ib. Changes occurring due to elimination of CLL cells and/or disruption of critical
CLL-TME interaction pathways are here referred to as indirect effects, exempli-
fied by CLL tumor-debulking by ibrutinib, idelalisib, or venetoclax, and disruption
of protective signaling between nurse-like cells/tumor-associated macrophages
and CLL cells by ibrutinib and idelalisib. Chimeric antigen receptor (CAR) T cells,
bispecific antibodies, and immune checkpoint blockade immunotherapy rely
directly on the engagement and activation of microenvironmental cells for anti-
CLL activity. Binding of CAR T cells to CD19 on CLL cells activates cytolytic anti-
CLL T-cell activity, bispecific antibodies redirect T cells into CLL cell proximity and
engage T-cell anti-tumor activity, and immune checkpoint blockade abrogates
checkpoint inhibitory signals unleashing the anti-CLL activity of tumor-infiltrating
T cells. CLL: chronic lymphocytic leukemia; BTK: Bruton tyrosine kinase; SYK:
spleen tyrosine kinase; PI3Kδ: phosphoinositide-3-kinase δ, BCR: B-cell recep-
tor; TCR: T-cell receptor; ITK: interleukin-2-inducible T-cell kinase BCL-2: B-cell
leukemia/lymphoma-2; TME: tumor microenvironment; NLC: nurse-like cells;
TAM: tumor-associated macrophages; CAR T: chimeric antigen receptor T cells;
CD: cluster of differentiation; PD-1: programmed cell death protein-1; PD-1L: pro-
grammed cell death protein-1 ligand.
A
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exhaustion/chronic activation T-cell phenotype illustrated
by PD-1 downregulation,33,35 supporting the concept that
ibrutinib improves T-cell function. Similarly, treatment
with acalabrutinib and zanubrutinib downregulated T-cell
PD-1 expresssion.35,40 Thus, reduced exhaustion pheno-
types could be due to indirect removal of tumor burden by
all three BTK inhibitors. However, improved T-cell func-
tionality may also be due to differential effects on CD4+
and CD8+ subsets, which could be linked to direct off-tar-
get activity of ibrutinib.
ITK has particular importance for Th2 T-cell polarization
as well as for the development of Treg. Ibrutinib promoted
Th1 polarization in a CLL mouse model,38 but this has been
more challenging to detect in patients receiving therapy.35
Furthermore ex vivo ibrutinib treatment of γδ T cells from
CLL patients promoted a Th1 phenotype leading to
improved antitumor effector function, indicating effects
due to direct off-target ITK inhibition.42 Ibrutinib treat-
ment also reduced the fraction of Treg in CLL patients,43
while treatment with acalabrutinib did not affect Treg num-
bers, further indicating direct off-target ITK inhibition by
ibrutinib.35,43 Reduced numbers of CD4+ IL-17 producing Th
cells (Th17 cells) in ibrutinib-treated patients, as well as
reduced Th17 differentiation in vitro, have also been
demonstrated, recapitulating findings from ITK knockout
mice.33 As for Treg, acalabrutinib did not affect Th17-cell
numbers.35 However, contradictory findings, with
increased Th17 T cells in patients with CLL receiving ibru-
tinib, have been reported.35 This is perhaps due to complex
CD4+ subset changes which are related to time on therapy
and prior treatment history in study cohorts. Additionally,
although current data support ibrutinib-mediated direct
ITK inhibition in both Th17 and Treg subsets, given their
antagonizing roles,44 indirect effects on Th17 T cells due to
reductions of Treg may “dominate” the direct effects, and
contribute to this compartment expanding.
Inhibition of B-cell receptor signaling leading to redistri-
bution of CLL cells from sanctuary niches into the periph-
eral blood is a hallmark of ibrutinib treatment,45 the mech-
anism of which is, in part, disruption of microenviron-
mental interactions. Bone marrow specimens from ibruti-
nib-treated patients revealed disruption of (tumor-associ-
ated) macrophage-CLL cell contacts, with macrophage
cellular protrusions contracting during therapy, likely
reflecting a loss of NLC pro-survival signaling.33 Ibrutinib
has been shown to block BTK and downstream transcrip-
tion factors within macrophages, resulting in downregu-
lated expression of the chemokines CXCL12 and
CXCL13, thus suggesting a direct effect of ibrutinib on
macrophages.46 The reduced levels of these chemokines
further compromised adhesion and migration of malig-
nant B cells in vitro.46 In accordance, ibrutinib-mediated
inhibition of the migratory response of CLL cells towards
these chemokines was demonstrated.33,47 Thus, direct
effects of ibrutinib on macrophages seem to mediate
inhibited CLL-cell chemotaxis and adhesion, thereby like-
ly contributing significantly to the clinical reduction in
lymph node and spleen size, and concomitant peripheral
lymphocytosis.45 Contrariwise, unfavorable effects of
ibrutinib, including impaired phagocytosis in
macrophages and neutrophils, and inhibited NK-cell acti-
vation and suppressed antibody-dependent cellular cyto-
toxicity by NK cells have been demonstrated, likely relat-
ed to direct inhibition of BTK and ITK by ibrutinib in
these cells. This may have important clinical implications
for combination treatment with CD20 antibodies.48
Reduction of MDSC and a concomitant increase in clas-
sical monocytes were recently demonstrated in patients
with CLL after 12 months of ibrutinib treatment,36 and
were likely due to both direct effects of BTK inhibition in
MDSC,49 and indirect effects induced through reduced
tumor burden. Given their suppressive effect on T-cell
function,23 a reduction of MDSC may also further con-
tribute indirectly to improved T-cell/immune functions.
Moreover, ibrutinib abrogates the adherence of vascular
cell adhesion molecule-1-positive CLL cells to fibronectin
on stromal cells, thereby further reducing the ability of
CLL cells to remain in the protective tissue niches.47,50
Although ibrutinib produces impressive clinical results,
treatment resistance is emerging,6 and residual disease
remains a challenge. In vitro studies have demonstrated a
protective effect of NLC in the presence of ibrutinib,
thereby implying a role for NLC in contributing to residual
disease and the development of ibrutinib resistance.7
Furthermore, it was demonstrated that ibrutinib-resistant
subclones harboring BTK mutations promote proliferation
of BTK wild-type cells during ongoing ibrutinib treatment
through paracrine stimulation, further implying a role of
microenvironment crosstalk in the development of resist-
ance.8
A number of studies seem to point toward improved
clinical immune function due to the TME modulations
mediated by ibrutinib.51,52 This issue, however, remains
controversial, as there is still a lack of data demonstrating
reduced risk of infections compared to prior ibrutinib
treatment. However, studies do indicate that restoration
of immune phenotypes and function establish after long-
term treatment.33,34,36,51 This is in line with previous real-
world data demonstrating that infectious adverse events
in patients with CLL treated with ibrutinib are most fre-
quent during the first 6 months, after which infection rates
decline.53 Thus, the long-term indirect effects of ibrutinib
due to reduced tumor burden and disrupted CLL-TME
crosstalk may allow the various immune cell compart-
ments to re-establish normal host immunity; however,
further studies on this matter are warranted. 
Continued investigation of the impact of BTK inhibitors
on the TME compartments is warranted in order to pro-
vide tailored treatment strategies to improve clinical out-
come (residual and progressive disease) and immune func-
tion in patients with CLL, while evading emergence of
drug resistance. The most important effects of BTK
inhibitors on the TME are summarized in Table 1 and
illustrated in Figure 2.
PI3K inhibitors
In addition to BTK, PI3K constitutes another critical
component of the B-cell receptor signaling pathway (Figure
2). Idelalisib is a selective inhibitor of PI3Kδ, the PI3K iso-
form generally restricted to hematopoietic cell types,54 and
was the first PI3K inhibitor approved for CLL treatment. In
preclinical studies, idelalisib induced caspase-dependent
apoptosis of primary CLL cells and also reduced their
chemokine secretion, independently of cytogenetics or
IgHV mutational status.55,56 Although treatment of autolo-
gous T cells and NK cells with idelalisib does not induce
apoptosis in these cells, it does decrease their production of
inflammatory cytokines (IL-6, IL-10, tumor necrosis factor-
R. Svanberg et al.
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α [TNF-α], interferon [IFN]-γ) and activation-induced mol-
ecules (CD40L).55 These changes could potentially have
effects on both pro-tumor and antitumor immune func-
tions. In addition, idelalisib antagonizes the CLL pro-sur-
vival functions of TNF-α and CD40L.55 The effect of idelal-
isib on the Treg subset has been a focus of previous studies,
as inactivation of PI3Kδ in mice impaired Treg-mediated
immune tolerance, enhancing CD8+ T-cell mediated cyto-
toxic responses towards tumor cells.57 Interestingly, PI3Kδ
inhibition in a CLL mouse model resulted in reduced num-
bers and maturation of Tregs; however, this did not result in
enhanced antitumor CD8+ T-cell function, likely due to
concomitant direct inhibition of PI3Kδ downstream of T-
cell receptor signaling.58
Similar to the effects of ibrutinib, idelalisib seems to
interfere with CXCL12-mediated chemotaxis, and abro-
gates adhesion of CLL cells to stromal cells, suggesting an
indirect mechanism through disrupting the protection of
CLL cells provided by the TME.9,56 This correlates with
clinical findings of reduced lymphadenopathy and
splenomegaly concomitant with lymphocytosis and sig-
nificantly reduced levels of CLL-related chemokines.59 It
has been demonstrated that idelalisib impairs neutrophil
function ex vivo,60 which together with changes in cytotox-
ic T-cell subsets and strong suppression of Treg, likely con-
tribute to the increased immune-related adverse events
and increased risk of infections observed upon idelalisib
treatment in clinical trials.61 The next-generation PI3K
Targeting the tumor microenvironment in CLL
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Table 1. Effect of novel therapeutic agents on the microenvironment in chronic lymphocytic leukemia. 
Population                Agent                                                      Functional changes 
T cells
                                        BTK inhibitors                                                   Increased T-cell receptor diversity34,37 (ibr)
                                        -ibrutinib (ibr)                                                 Enhanced T-cell lytic immune synapse function52 (ibr)
                                        -acalabrutinib (aca)                                        Skewing towards Th1 polarization23,53,54 (ibr)
                                        -zanubrutinib (zan)                                         Reduced T-cell PD-1 expression/exhaustion phenotype49,51,67 (ibr, aca, zan)
                                                                                                                      Reduced number of Treg51,55 (ibr)
                                        PI3K inhibitors                                                  Reduced secretion of inflammatory cytokines70 (id)
                                        -idelalisib (id)                                                  Inhibition of Treg functions73,79 (id, duv)
                                        -duvelisib (duv)
                                        BCL-2 inhibitors                                               Reduced number of T cells70 (ven)
                                        -venetoclax (ven)                                            Reduced number of Treg70 (ven)
                                                                                                                      Decreased T-cell PD-1 expression70 (ven)
                                        IMiD/CELMoD                                                  Immune activation, repaired T-cell dysfunction20,24,90,91 (len)
                                        -lenalidomide (len)                                         Suppressed T-cell proliferation93 (len)
                                        -avadomide (ava)                                             Promotion of Th1 polarization92 (len)
                                                                                                                      Induction of inflammatory IFN type I and II signaling in previously exhausted T-cells27 (ava)
Myeloid cells
                                        BTK inhibitors                                                   Abrogation of the protective contact49 (ibr)
                                        -ibrutinib (ibr)                                                 Inhibited chemokine signaling and mediation of CLL cell homing58,59 (ibr) 
                                                                                                                      Impaired phagocytosis by macrophages and neutrophils48 (ibr)
                                                                                                                      Reduced number of MDSC and increased classical monocytes36 (ibr)
                                        PI3K inhibitors                                                  Impaired neutrophil inflammatory responses76 (id)
                                        -idelalisib (id)
                                        IMiD                                                                    Impaired migration/chemotaxis, abrogated CLL cell protective capability, 
                                        -lenalidomide (len)                                         increased phagocytosis93 (len)
Stromal cells
                                        BTK inhibitors                                                   Revoked adherence to stromal cells in protective niches59,60 (ibr)
                                        -ibrutinib (ibr)
                                        PI3K-inhibitors                                                 Reduced chemotaxis and impaired adhesion71,74 (id)
                                        -idelalisib (id)
NK cells
                                        BTK inhibitors                                                   Inhibited NK-cell activation48 (ibr)
                                        -ibrutinib (ibr)                                                 Suppressed ADCC48 (ibr)
                                        PI3K inhibitors                                                  Reduced secretion of inflammatory cytokines70 (id)
                                        -idelalisib (id)
                                        BCL-2 inhibitors                                               Decreased number of NK cells70
                                        -venetoclax (ven)                                            Improved NK-cell function70
CLL: chronic lymphocytic leukemia; BTK: Bruton tyrosine kinase; ITK; interleukin-2-inducible T-cell kinase; BCL-2: B-cell lymphoma 2; Th: T helper; PD-1: programmed cell death
protein 1; Treg: regulatory T-cell; PI3K: phosphoinositide 3’-kinase; IMiD: immunomodulatory drugs; CELMoD: cereblon E3 ligase modulators; IFN: interferon; MDSC: myeloid derived
suppressor cells; ADCC: antibody-dependent cellular cytotoxicity.
inhibitor, duvelisib, a dual inhibitor of PI3K isoforms δ and
γ, was recently approved for the treatment of
relapsed/refractory CLL. Similar to idelalisib, treatment
with duvelisib entails increased risk of immune-related
toxicities and infections in patients with CLL,62 likely also
due to strong direct inhibitory effects on Treg and cytotoxic
T-cell effector function as demonstrated in a CLL mouse
model.63 In contrast, another next-generation PI3K
inhibitor, umbralisib, with dual PI3Kδ/casein kinase-1-e
(CK1e) inhibitory activity, did not modulate Treg function,
which was associated with lower toxicity in a murine
model.63 Thus, the disadvantageous direct effects of idelal-
isib and duvelisib on T-cell subsets contributing to a risk of
infections and toxicity, which have hampered their clinical
usage, could potentially be mitigated with the use of
umbralisib due to altered PI3K specificity. The most
important effects of PI3K inhibition on the TME are sum-
marized in Table 1 and illustrated in Figure 2.
BCL-2 inhibitors
The anti-apoptotic regulatory protein B-cell lymphoma
2 (BCL-2) is constitutively upregulated in several lym-
phomas including CLL, hence playing a dominant role in
blocking apoptotic signaling and promoting survival in
these malignancies.64 Venetoclax (ABT-199), a selective
BCL-2 inhibitor, demonstrated the ability to induce rapid
apoptosis in primary CLL cells in vitro and in xenograft
models65 (Figure 3). In clinical trials, venetoclax alone or
combined with an anti-CD20 antibody has achieved deep
and durable undetectable minimal residual disease in
patients with CLL.64,66 However, while leukemic cells are
highly dependent on BCL-2, the dependence of non-
leukemic cells on this protein seems to vary substantially.
The high prevalence of grade 3/4 neutropenia among
patients treated with venetoclax likely reflects the relative-
ly marked dependency of granulopoiesis on BCL-2.67 T-cell
homeostasis also depends on BCL-2, however with vari-
able impact on different T-cell subsets. While murine
naïve T cells were found to be highly dependent on BCL-
2, the protein was dispensable for memory T cells.68
Coherently, a decrease in naïve T-cell subsets and
increased memory T cells have also been reported in both
mice and healthy human subjects receiving venetoclax69
(Figure 3). A study on CLL patients treated with veneto-
clax and the CD20 antibody obinutuzumab documented
decreased numbers of normal B cells, NK cells, and T cells,
including Tregs, in the peripheral blood. In addition, a
decrease in the exhausted/chronically activated PD1+ T-
R. Svanberg et al.
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Figure 2. Effects of BTK inhibitors on the chronic lymphocytic leukemia tumor microenvironment. Inhibitory effects are represented by bars, stimulatory effects are
represented by arrows. Upward arrows indicate increases, downward arrows indicate decreases. CLL: chronic lymphocytic leukemia; TME: tumor microenvironment;
BTK: Bruton tyrosine kinase; BTKi: BTK inhibitor; ITK:interleukin-2-inducible T-cell kinase; PI3Kδ: phosphoinositide-3-kinase δ; TCR: T-cell receptor; CD: cluster of dif-
ferentiation; CD40L: CD40 ligand; IL: interleukin; TNF: tumor necrosis factor; IFN: interferon; PD-1: programmed cell death protein 1; Th: T helper; Treg: regulatory T
cell; ADCP: antibody-dependent cellular phagocytosis; VCAM: vascular cell adhesion molecule; VLA, very late antigen; CXCL: CXC motif chemokine; MDSC: myeloid-
derived suppressor cells.
cell phenotype was observed, along with improved NK-
cell function, and reductions of the levels of elevated
inflammatory cytokines70 (Figure 3). The authors interpret-
ed these changes as being indirect effects due to eradica-
tion of the leukemic cells, and any direct effects on these
cells by venetoclax were not investigated. Critically, the
TME also appears to play a role in venetoclax resistance.
In a previous study, in vitro CD40/CD40L co-stimulation
strongly reduced sensitivity to venetoclax through upreg-
ulation of other anti-apoptotic proteins, such as myeloid
cell leukemia 1 (MCL-1) and B-cell lymphoma extra large
(BCL-XL), in CLL cells.71 The varying dependency on BCL-
2 among different microenvironmental cell types, as well
as between patients, warrants further investigation, in
order to optimize the advantages of targeting the apoptot-
ic pathway in malignant cells, and utilize potential
immunomodulatory effects in the immune TME while
minimizing disadvantageous on-target-but-off-leukemic
effects leading to adverse events.  
Immunomodulatory drugs
Lenalidomide is an immunomodulatory drug (IMiD)
widely used to treat multiple myeloma. Despite having no
direct cytotoxicity against CLL cells in vitro,72 clinical activ-
ity in patients with CLL has been demonstrated,73,74 sup-
porting anti-CLL immunomodulatory effects in the TME
as a principle mode of action. In vitro, lenalidomide induces
downregulation of CLL immune checkpoint receptors on
T cells, suggesting treatment-induced immune activation
or reversal of exhaustion.15 Moreover, lenalidomide treat-
ment of autologous T cells and CLL cells triggers repair of
T-cell dysfunction. This results in improved synapse for-
mation, granzyme B- and IL-21-mediated cytotoxicity,
enhanced CD8+ T-cell effector killing, and restored LFA-1-
mediated T-cell motility.14,75–77 Supporting this, in vivo sam-
ples from treated patients revealed changes in the compo-
sition of the T-cell subpopulations and their cytokine pro-
duction.78 Lenalidomide also affects CLL monocytes/NLC.
The presence of lenalidomide impaired migration of CLL-
supportive monocytes towards CCL2, CCL3, and
CXCL12 in in vitro chemotaxis assays.79 The same study
demonstrated downregulation of genes associated with
pro-survival signals for CLL cells and impaired protective
ability of NLC.79 Moreover, CLL-induced immunosuppres-
sion was reversed by lenalidomide, with improved phago-
cytotic activity, cytokine production, T-cell stimulatory
and proliferative activity.79 Lenalidomide has produced
clinical responses as monotherapy,74 in combination with
rituximab or with chemotherapy,80 and as maintenance
following chemotherapy.73 However, increased risk of tox-
icities and infections with treatment remains a concern,73
potentially reflecting potent activation of the immune
TME with this class of drug. Thus, the place and dosing
regimen for lenalidomide in clinical practice remain
unclear. A novel option emerging for CLL therapy are
next-generation cereblon E3 ligase modulators (CELMoD),
with avadomide recently investigated in a preclinical
study. Avadomide stimulated T-cell activation, the expres-
sion of immunostimulatory chemokines, and the forma-
tion of lytic synapses with CLL cells by triggering inflam-
matory IFN type I and II signaling in previously exhausted
T cells from patients.81 The potential and optimal roles of
IMiD and CELMoD in the context of the CLL-TME
remain to be determined; however, the favorable
immunomodulatory effects on the T-cell/NK-cell com-
partments imply a role for IMiD and CELMoD in develop-
ing novel combination treatment strategies. The most
important effects of IMiD/CELMoD on the TME are sum-
marized in Table 1 and illustrated in Figure 3. 
Immune checkpoint blockade
The PD-1:PD-L1 is an immune checkpoint pathway
used by tumor cells to inhibit T cells and escape immune
surveillance. Thus, this pathway constitutes an attractive
therapeutic target (Figure 4).82 Blocking PD-L1 in CLL-
transplanted mice resulted in repressed disease develop-
ment and restored T-cell immune effector functions
including improved cytotoxicity, cytokine production, and
immune synapse formation.83 Despite this, the sparse clin-
ical data on immune checkpoint blockade (ICB) in CLL are
disappointing. In a phase II study of the PD-1 blocking
antibody drug, pembrolizumab, four out of nine patients
with Richter transformation showed clinical response to
treatment, whereas none of the 16 CLL patients respond-
ed.84 The clinical efficacy of ICB-based therapy correlates
with upregulated levels of tumor PD-L1 expression that is
associated with an “inflamed” microenvironment with the
presence of activated cytotoxic tumor-infiltrating T cells
attempting to engage tumor cells, which can be unleashed
as checkpoint inhibitory signals are abrogated.85 PD-L1
expression on CLL cells is relatively low, likely reflecting
low activity of cytolytic T cells.81,82 Furthermore, the
immunosuppressive state of the TME in CLL, with pro-
foundly exhausted effector T cells that exhibit multiple
functional defects, likely contributes significantly to the
lack of clinical response to checkpoint inhibitor monother-
apy in CLL patients. Consistent with this, a recent study
of patients’ lymph node biopsies has provided evidence
for a non-inflamed microenvironment in CLL, incorporat-
ing low numbers of CD8+ T cells, low PD-L1 expression
and profound T-cell exhaustion.81 Thus, strategies that can
subvert the strong immunosuppressive pressure of the
CLL-TME and overcome T-cell dysfunction may be neces-
sary to sensitize CLL to ICB immunotherapy and develop
therapeutic options for CLL patients. Further research to
unravel the complex immunosuppression in the CLL-TME
is warranted in order to develop and optimize immuno-
oncology treatments.  
T-cell-based therapy
Chimeric antigen receptor (CAR) T cells have emerged
as a powerful therapeutic option designed to transfer high
numbers of tumor-targeted effector T cells into the TME
to overcome a paucity of endogenous cytolytic T cells.
Briefly, autologous T cells are genetically modified to
express CAR with specificity for specific tumor antigens,
such as CD19 in B-cell malignancies, thus creating an
adoptive T-cell-mediated cytotoxic response (Figure 4).86
CAR T cells combine the effects of T-cell and antibody-
mediated immune responses by triggering T-cell activa-
tion with granule exocytosis upon antigen binding.87
Despite the first successful CAR T-cell trial being reported
in CLL, few clinical trials have subsequently reported effi-
cacy of CAR T cells in CLL.88 CLL-induced T-cell dysfunc-
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tion, as well as understudied lymphoid TME barriers, like-
ly reduce the efficacy of this approach in CLL. A recent
study revealed that CAR T cells from CLL patients
responding well to CAR T-cell therapy expressed upregu-
lated genes associated with T-cell memory. Furthermore,
enriched T-memory subsets prior to CAR T-cell generation
correlated with sustained remissions. Meanwhile, CAR T
cells from non-responders had upregulated genes associat-
ed with effector T-cell differentiation, apoptosis and
exhaustion, thus emphasizing that T-cell fitness is crucial
for the efficacy of CAR T cells.89 Due to the multitude of
(successful) treatment options for CLL currently, CAR T-
cell therapy may first become a relevant option in treating
multi-relapsed disease, and preliminary reports from cur-
rent clinical trials of CD19-targeted CAR T-cell therapy in
patients with multi-relapsed CLL show somewhat encour-
aging results.90 However, paradoxically, T-cell exhaustion
in CLL is demonstrated to worsen with progressive dis-
ease,13 thus pointing towards a need for options that
improve T-cell function prior to the manufacture of CAR T
cells or during treatment. Furthermore, it was recently elu-
cidated that CLL cells can directly impair CAR T-cell func-
tion and induce an exhausted phenotype through the
release of plasma extracellular vesicles.91 Thus, a meaning-
ful role for CAR T-cell therapy in CLL may rely on the abil-
ity of current and/or future therapies to successfully target
the TME and improve T-cell fitness in patients with CLL,
prior to the CAR T-cell treatment, during preparation of
the product, and after its administration. 
A novel therapeutic approach that could constitute an
alternative to CAR T-cell therapy is off-the-shelf bispecific
CD19/CD3 or CD20/CD3 antibody treatment. Bispecific
antibodies simultaneously engage CD3 on T cells and
CD19 or CD20 on target B cells, and thereby redirect T
cells to recognize CLL cells, facilitating synapse formation
and, thus, T-cell-mediated antitumor responses (Figure 4).
Preclinical studies using bispecific antibodies have demon-
strated antileukemic activity against CLL cells in vitro and
in xenograft models.92 Thus, bispecific antibodies may
constitute a promising T-cell-based immunotherapeutic
approach for CLL, alone, or in combination with TME-
modulating agents that help improve T-cell function. 
Developing combination strategies targeting
the chronic lymphocytic leukemia – tumor
microenvironment
It is becoming evident that improving clinical responses
(residual and progressive disease), overcoming toxicity,
infection risk, as well as drug resistance, likely require
strategies aimed at reshaping the immunosubversive, pro-
tumor TME state. Our improved understanding of the
direct and indirect CLL-TME modulations by novel thera-
peutic agents in recent years provides a unique opportuni-
ty to optimize CLL treatment with strategic drug combi-
nations that target multiple CLL-TME interactions to
achieve therapeutic synergy while controlling toxicity. 
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Figure 3. Effects of BCL-2 inhibitors, immunomodulatory drugs, and cereblon E3 ligase modulation on the tumor microenvironment. Inhibitory effects are repre-
sented by bars, stimulatory effects are represented by arrows. Upward arrows indicate increases, downward arrows indicate decreases. CLL: chronic lymphocytic
leukemia; TME: tumor microenvironment; BCL-2: B-cell lymphoma 2; BCL-2i: BCL-2 inhibitor; IMiD: immunomodulatory drug; CELMoD: cereblon E3 ligase modulator;
TCR: T-cell receptor; HLA-DR: human leukocyte antigen DR-isotype; IFN: interferon; PD-1: programmed cell death protein 1; PD-1L: programmed cell death protein-1
ligand; CCL: chemokine ligand.
Monoclonal antibodies targeting the B-cell surface pro-
tein CD20 have been the backbone of standard chemo-
immunotherapy regimes used to treat CLL for decades,
although they are rarely used as a monotherapy in CLL.1
Major mechanisms of action of anti-CD20 antibodies are
activation of antibody-dependent cellular cytotoxicity and
antibody-dependent cellular phagocytosis, which rely on
engaging the antitumor activity of NK cells and mono-
cytes/macrophages within the immune TME.1,48,93 The
direct inhibitory effects of ibrutinib on macrophage
phagocytosis and NK-cell activation may therefore inter-
fere with the therapeutic efficacy of anti-CD20
treatment.48 Compared to ibrutinib as a single agent,
adding an anti-CD20 antibody to ibrutinib was associated
with faster remissions and lower levels of residual disease
in a clinical trial, although it was not demonstrated that
the combination improved progression-free survival.94
Thus, whether this combination is beneficial remains
debatable. In contrast, combining anti-CD20 antibodies
with venetoclax seems to improve the phagocytosis of
CLL cells by macrophages in vitro,93 and reverse venetoclax
resistance induced by TME signaling.71 Interestingly,
although venetoclax plus anti-CD20 treatment produces
impressive clinical responses in clinical trials, a recent ret-
rospective study including real-world data demonstrated
comparable efficacy between venetoclax as a single agent
and venetoclax plus anti-CD20 combination treatment in
high risk relapsed/refractory CLL patients.95 Thus, further
validating prospective studies are warranted to determine
whether the addition of an anti-CD20 antibody to veneto-
clax is truly necessary.
The addition of venetoclax to ibrutinib constitutes
another approach aiming to provide improved duration
and depth of remissions as well as to enable fixed-dura-
tion treatment, which has already, in part, demonstrated
success in clinical trials.96 Similarly, the PI3K inhibitor,
duvelisib, increases sensitivity of CLL cells to venetoclax,
providing the rationale for duvelisib-venetoclax combina-
tion treatment, currently being investigated in clinical tri-
als.97
However, the biggest challenges ahead involve finding
strategic combinations that overcome T-cell dysfunction,
improve the efficacy of T-cell-based therapies and ICB in
CLL, and work towards curative therapy. Data from a
human xenograft model support the ability of ibrutinib to
enhance CAR T-cell function when administered concur-
rently.98 Similarly, another murine study indicated that
PI3Kδ inhibition during CAR T-cell production may have
a positive effect on engraftment and antitumor activity.99
Consistently with this, a clinical pilot study recently
demonstrated high response rates in relapsed/refractory
CLL patients receiving ibrutinib concomitant with CD19-
targeted CAR T-cell therapy, and lower toxicities com-
pared to those in patients treated without concomitant
ibrutinib.100 Furthermore, T cells from ibrutinib-treated
CLL patients seem to exhibit improved in vitro anti-CLL
activity combined with bispecific antibodies.101
The lack of clinical activity of anti-PD-1 monotherapy in
CLL,84 has highlighted the need to incorporate ICB thera-
pies into more powerful combinations to unleash the
power of antitumor immune cells. Studies of PD-1:PD-L1
blockade combined with ibrutinib have demonstrated
enhanced CD8+ T-cell function along with improved dis-
ease control in a CLL mouse model.102 However, prelimi-
nary clinical results have indicated that coupling anti-PD-
1 with ibrutinib may not increase response rates in
Targeting the tumor microenvironment in CLL
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Figure 4. Effects of immune
checkpoint blockade, chimeric
antigen receptor T cells, and bis-
pecific antibodies. Arrows point
out the actions of immune check-
point blockade, chimeric antigen
receptor T cells and bispecific anti-
bodies, leading to engagement
and activation of the tumor
microenvironment for anti-chronic
lymphocytic leukemia activity.
Upward arrows indicate increases.
CLL: chronic lymphocytic
leukemia; PD-1: programmed cell
death protein 1; PD-1L: pro-
grammed cell death protein-1 lig-
and; Ab: antibody; CAR-T: chimeric
antigen receptor T cells; bsAB: bis-
pecific antibodies; TCR: T-cell
receptor; CD: cluster of differentia-
tion.
patients.103 PI3K inhibition improved the anticancer effect
of ICB through modulatory effects on MDSC in a solid
cancer in vitro model,104 thus highlighting additional roles
of PI3K inhibition in modulation of the TME which could
be exploited. The relative expansion of memory T-cell
subsets due to direct effects of venetoclax on other, more
BCL-2-dependent T-cell subsets, support a role for veneto-
clax in combination with ICB. In a recent sold cancer
murine study, venetoclax augmented the antitumor effect
of anti-PD-1 and anti-PD-L1 inhibitors in vivo.69
Through their potent activation of T cells, CELMoD and
IMiD could represent strong complementary treatment
partners for combination (immune)therapy.14,15,73,75,76,80,81 It
has been demonstrated preclinically that the CELMoD
avadomide could sensitize CLL to anti-PD-1 or anti-PD-L1
immunotherapy.81 By inducing inflammatory interferon
type I and II signaling in previously exhausted T cells from
patients, avadomide stimulated the proliferation and
release of chemokines by T cells which recruited addition-
al CD8+ T cells, upregulated PD-L1 in the immune TME,
and enhanced lytic synapse formation.81
Even more powerful combinations could include pairing
ICB with CAR T cells or bispecific antibodies to increase
tumor infiltrating T cells, or dual ICB combinations to
overcome additional inhibitory barriers. T-cell bispecific
antibodies combined with an anti-PD-L1 antibody
showed enhanced antitumor efficacy compared to either
given alone in a solid cancer mouse model.105 Furthermore,
a recent CLL murine study demonstrated that anti-PD1
ICB combined with inhibition of the immune checkpoint
receptor lymphocyte-antigen gene 3 (LAG3) was able to
decrease tumor load significantly, while either as
monotherapy had little effect.106
Thus, developing combination immunotherapy could
represent a powerful strategy for deepening targeted drug
(e.g., BTK inhibitor- and/or venetoclax)-induced responses
and working towards curative therapy in CLL.
Future perspectives: novel targetable tumor
microenvironment interactions
The CLL-TME constitutes a landscape of potential tar-
getable pathways. Antibodies interrupting the
CXCL12/CXCR4 interaction have demonstrated anti-CLL
activity in vitro and in mouse models, and have been tested
in phase I clinical trials for multiple myeloma, but have
not yet been further explored in CLL.107 The BAFF/BAFF-R
axis constitutes another attractive CLL-TME interaction to
target. An anti-BAFF-R antibody blocked protective sur-
vival signaling in CLL cells and enhanced antibody-depen-
dent cellular cytotoxicity in vitro, and also enhanced effica-
cy of ibrutinib in a CLL mouse model.108 Targeting of an IL-
10-producing CD38hi regulatory B cell-like CLL subset is
also currently under investigation.27 Although aimed at
CLL cells, the anti-leukemic potential here would be medi-
ated indirectly by abrogating IL-10-mediated immunosup-
pression. The “don’t eat me” signal regulatory protein
(SIRP)1α/CD47 axis, co-expressed by macrophages and
malignant cells, respectively, in various lymphoid malig-
nancies including CLL, constitutes a mechanism of
myeloid immune tolerance. It is currently being explored
as a potential target in lymphoma, and may also constitute
an important macrophage-CLL interaction with targetable
potential.109 Furthermore, MDSC-derived indoleamine 2,3-
dioxygenase (IDO) has been explored as a target in other
cancers, as an antitumor vaccination antigen.110 Mediating
strong immunosuppressive effects in the CLL-TME, IDO
may constitute another potentially attractive interaction
to target in CLL. 
In conclusion, the heterogeneous course of CLL is driv-
en by (i) the genetic complexity and (ii) diverse and com-
plex tissue TME interactions, including (iii) antigenic
drive. The functionally and phenotypically skewed cell
types within the TME not only promote CLL itself, but
also compromise the induction of adequate immune
responses towards developing and progressing CLL
clones, as well as infectious agents. Thus, further explo-
ration of the impact of different therapies on critical
microenvironmental interactions is warranted. This
review was intended to outline our current understanding
of how CLL-TME interactions are influenced by current
CLL therapies, with the view to encourage continued
mapping of the CLL-TME for more specific future target-
ing of CLL-TME crosstalk. The inclusion of translational
correlative studies assessing immunological and TME
changes within clinical trials should inform development
of novel combination therapies beyond BTK inhibitors
and BCL-2 inhibitors. These include, but are not limited
to, checkpoint inhibitors, T-cell based therapies, and TME
modulation overcoming the inherent immune exhaustion
in CLL. Such strategies together with further understand-
ing of the TME should, eventually, lead to improved and
more personalized treatment options aiming for a clinical
cure with reduced burden of adverse events for patients
with CLL.
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